Vistagen will present at the?Anxiety and Depression Association of America (ADAA) Conference?in?Las Vegas, Nevada from April 3-5th. Poster presentations will explore the age of onset of social anxiety disorder (SAD) from fasedienol clinical trial participants, and new data on young adults with and without SAD. For details: https://bit.ly/3E3QBEy #ADAA2025
Vistagen
制药业
South San Francisco，California 4,326 位关注者
Changing the trajectory of mental health care – One Mind at a Time
关于我们
Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage company leveraging its pioneering neuroscience and deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of intranasal product candidates called pherines. Each pherine product candidate in Vistagen’s neuroscience pipeline is designed to rapidly activate olfactory system and brain neurocircuitry to achieve desired therapeutic benefits and differentiated safety without requiring systemic absorption or binding to neurons in the brain. Vistagen’s neuroscience pipeline also includes an oral prodrug, AV-101, with potential to impact certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent disorders, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. Connect at www.vistagen.com.
- 网站
-
https://vistagen.com
Vistagen的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- South San Francisco，California
- 类型
- 上市公司
- 创立
- 1998
地点
-
主要
获取路线
343 Allerton Ave
US，California，South San Francisco，94080
Vistagen员工
动态
-
Today at 12:00pm ET, Shawn Singh will participate in a fireside chat during @Stifel’s 2025 Virtual CNS Forum. Watch the live webcast here: https://bit.ly/43IzAKC
-
-
?? On #CelebrateScientistsDay, we proudly recognize our very own Louis Monti, M.D., Ph.D. Dr. Monti is the pioneering mind behind pherines, our groundbreaking new class of intranasal product candidates harnessing the power and therapeutic potential of nose-to-brain neurocircuitry. Dr. Monti’s work is at the forefront of our mission to develop innovative, fast-acting solutions for multiple unmet medical needs. His commitment to neuroscience is helping to redefine what’s possible in mental health care, women’s health, and more. Join us in celebrating Dr. Monti and all the scientists at Vistagen and across the biopharmaceutical industry working to shape a brighter future! ?? #CelebrateScientistsDay #MentalHealthInnovation #Pherines #ScienceForGood
-
-
Vistagen's CEO, Shawn Singh, will participate in a fireside chat during Stifel’s 2025 Virtual CNS Forum on Tuesday, March 18 at 12:00pm ET. For details, visit: https://bit.ly/4i6cthE
-
-
Today's neuroscience breakthroughs are redefining mental health treatment, with our novel nose-to-brain neurocircuitry approach leading the charge. Our CEO, Shawn Singh, JD, joined Brandon Li on the Power to the Patients podcast to discuss our pioneering approach and the potential of pherines. Listen here: https://apple.co/4bladk2
-
Vistagen’s President and Chief Executive Officer, Shawn Singh, will present a corporate overview at the 45th Annual TD Cowen Healthcare Conference on Monday, March 3, 2025, at 2:30 p.m. ET. For more details: https://bit.ly/4i99rc3
-
-
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update: https://bit.ly/3CLX4Uf
-
-
Vistagen will host a conference call and webcast today, February 13 at 2:00 p.m. PT (5:00 p.m. ET) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. Watch here: https://bit.ly/3WOCAB8
-
-
Vistagen will host a conference call and webcast on Thursday, February 13 at 2:00 p.m. PT (5:00 p.m. ET) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. Register here: https://bit.ly/3WOCAB8
-
-
Vistagen today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of neuropathic pain. Read more: https://bit.ly/42I1juj
-